Medical Therapy. Pharmacokinetics and Pharmacology

Innovative Dual Combination Cospray-Dried Rock Inhibitor/l-Carnitine Inhalable Dry Powder Aerosols

Maria F. Acosta, David Encinas-Basurto, Michael D. Abrahamson, Basanth Babu Eedara, Don Hayes, Jr., Jeffrey R. Fineman, Stephen M. Black, Heidi M. MansourUniversity of Arizona College of Pharmacy. Universidad de Sonora. Florida International University. Ohio State University College of Medicine. Cincinnati Children’s Medical Center. University of California San Francisco School of Medicine. United States and […]

Innovative Dual Combination Cospray-Dried Rock Inhibitor/l-Carnitine Inhalable Dry Powder Aerosols Read More »

Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension

Lene Nygaard Axelsen, Anne Kümmel, Juan Jose Perez Ruixo, Alberto RussuActelion Pharmaceuticals and Johnson & Johnson, Allschwil. Janssen-Cilag S.p.A.Switzerland, Spain and Italy Clinical Pharmacology and Therapeutics: Pharmacometrics and Systems PharmacologyCPT Pharmacometrics Syst Pharmacol 2024;DOI: 10.1002/psp4.13231 AbstractSelexipag is an oral selective prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension (PAH) in adults. To date,

Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension Read More »

Oxygen saturation targets in neonatal care: A narrative review

Tri C. Nguyen, Rajeshwari Madappa, Heather M. Siefkes, Michelle J. Lim, Kanya Mysore Siddegowda, Satyan LakshminrusimhaKaiser Permanente North California. SIGMA Hospital. University of California Davis Children’s Hospital.United States Early Human DevelopmentEarly Hum Dev 2024; 199:DOI: 10.1016/j.earlhumdev.2024.106134 AbstractOptimal oxygenation requires the delivery of oxygen to meet tissue metabolic demands while minimizing hypoxic pulmonary vasoconstriction and oxygen toxicity.

Oxygen saturation targets in neonatal care: A narrative review Read More »

Inhalable Advanced Co-Spray Dried Microparticles/Nanoparticles of a Novel RhoA/Rho Kinase Inhibitor with Lung Surfactant Biomimetic Phospholipids for Targeted Lung Delivery

Victor H. Ruiz, David Encinas-Basurto, Neftali Ortega-Alarcon, Basanth Babu Eedara, Jeffrey R. Fineman, Stephen M. Black, Heidi M. MansourUniversity of Arizona College of Pharmacy, University of Arizona College of Medicine and University of Arizona. University of Sonora. Florida International University. University of California San Francisco School of Medicine. United States and Mexico American Chemical Society

Inhalable Advanced Co-Spray Dried Microparticles/Nanoparticles of a Novel RhoA/Rho Kinase Inhibitor with Lung Surfactant Biomimetic Phospholipids for Targeted Lung Delivery Read More »

Design and comprehensive characterization of dry powder inhalation aerosols of simvastatin DPPC/DPPG lung surfactant-mimic nanoparticles/microparticles for pulmonary nanomedicine

David Encinas-Basurto, Maria F. Acosta, Basanth Babu Eedara, Jeffrey R. Fineman, Stephen M. Black, Heidi M. MansourUniversity of Arizona. Biopolymers-CTAOA. Florida International University. University of California San Francisco School of Medicine. United States and Mexico Royal Society of Chemistry AdvancesRSC Adv 2024; 14: 29413-29427DOI: 10.1039/d4ra04947k AbstractThe Rho Kinase (ROCK) pathway is recognized to be involved in

Design and comprehensive characterization of dry powder inhalation aerosols of simvastatin DPPC/DPPG lung surfactant-mimic nanoparticles/microparticles for pulmonary nanomedicine Read More »

Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery

Heidi M. Manour, Priya Muralidharan, Don Hayes Jr.University of Arizona. Ohio State University College of Medicine. United States Journal of Aerosol Medicine and Pulmonary Drug DeliveryJ Aerosol Med Pulm Drug Deliv 2024; 37: 202-218 DOI: 10.1089/jamp.2024.29117.mk AbstractAn increasing growth in nanotechnology is evident from the growing number of products approved in the past decade. Nanotechnology can

Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery Read More »

The evolution of clinical trials for pediatric pulmonary hypertension: are the needs of patients and their caregivers being met?

Julie Wacker, Raphael Joye, Leon Genecand, Frederic Lador, Maurice BeghettiUniversity Hospitals of Geneva. Switzerland Expert Review of Clinical PharmacologyExpert Rev Clin Pharmacol 2024; DOI: 10.1080/17512433.2024.2396119 AbstractIntroduction: Pediatric pulmonary hypertension is a rare condition. Survival remains poor in the current management era. There is a lack of data regarding the medical management of pediatric pulmonary hypertension and most

The evolution of clinical trials for pediatric pulmonary hypertension: are the needs of patients and their caregivers being met? Read More »

Direct prostacyclin transition in pediatric patients with pulmonary hypertension

Kelly Merrill, Anne Davis, Emma Jackson, Meredith Riker, Christa Kirk, Delphine YungSeattle Children’s Hospital and University of Washington School of Medicine.United States Pulmonary CirculationPulm Circ 2024; 14: DOI: 10.1002/pul2.12373 AbstractPediatric patients with pulmonary arterial hypertension (PAH) are commonly treated with the prostacyclin analog treprostinil in IV, SQ, inhaled or oral form, or the prostacyclin receptor agonist

Direct prostacyclin transition in pediatric patients with pulmonary hypertension Read More »

Tailoring of Bilosomal Nanogel for Augmenting the Off-Label Use of Sildenafil Citrate in Pediatric Pulmonary Hypertension

Bjad K. Almutairy, El-Sayed Khafagy, Mohammed F. Aldawsari, Abdullah Alshetaili, Hadil Faris Alotaibi, Amr Selim Abu LilaPrince Sattam Bin Abdulaziz University. Suez Canal University. Princess Nourah Bint AbdulRahman University. Zagazig University. University of Hail.Saudi Arabia and Egypt American Chemical Society OmegaACS Omega 2024; 9: 19536-19547DOI: 10.1021/acsomega.4c01133 AbstractPediatric pulmonary hypertension is a serious syndrome with significant morbidity

Tailoring of Bilosomal Nanogel for Augmenting the Off-Label Use of Sildenafil Citrate in Pediatric Pulmonary Hypertension Read More »

Low global arginine bioavailability: a common phenomenon in pulmonary hypertension

Dunia Hatabah, Teresa De Marco, Dana P. McGlothlin, Mary Malloy, Loretta Z. Reyes, Rawan Korman, Gregory J. Kato, Claudia R. MorrisEmory University School of Medicine. University of California, San Francisco. Kaiser Permanente San Francisco. Children’s Healthcare of Atlanta. Blood Science Consulting.United States American Journal of Physiology Lung Cellular and Molecular PhysiologyAm J Physiol Lung Cell

Low global arginine bioavailability: a common phenomenon in pulmonary hypertension Read More »

Scroll to Top